Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game! 

Bio-Techne Corporation’s second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges. The company reported a 9% year-over-year increase in revenue, achieving $297 million in total sales, which was also the growth rate on an organic basis. This performance was largely fueled by significant contributions from the biopharma end markets, especially large pharmaceutical orders for Good Manufacturing Practice (GMP) reagents and protein analytical implementations, alongside notable strides in their ExosomeDx and spatial biology divisions.